Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 1, 2003, Pages 135-140

  Burger, Marilise E ^a   Alves, Audrei ^a   Callegari, Luciano ^a   Athayde, Fernanda R ^a   Nogueira, Cristina W ^a   Zeni, Gilson ^a   Rocha, João B T ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Antioxidant; Ebselen; Orofacial dyskinesia; Reserpine; Tardive dyskinesia; TBARS; Thiol peroxidase

Indexed keywords

ANTIOXIDANT; EBSELEN; RESERPINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; LIPID PEROXIDATION; MALE; MASTICATION; MUSCLE TWITCH; NEUROPROTECTION; NONHUMAN; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; RAT; TARDIVE DYSKINESIA;

EID: 84984576637     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00344-5     Document Type: Article

References (48)

1. Abilio V.C., Vera J.A.R., Ferreira L.S.M., Duarte C.R.M., Carvalho R.C., Grassl C.C., Martins C.R., Torres-Leite D., Bignotto M., Tufik S., Ribeiro R.A., Frussa-Filho R. Effects of melatonin on orofacial movements in rats. Psychopharmacology. 161:2002;340-347.
2. Andreassen O.A., Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 61:2000;525-541.
3. Baldessarini R.J., Tarazi F.I. Drugs and the treatment of psychiatric disorders. Hardman J.G., Limbird L.E., Gilman A.G. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 2001;485-520. New York.
4. Bergamo M., Abílio V.C., Queiroz C.M.T., Barbosa-Júnior H.N., Abdanur L.R.A., Frussa-Filho R. Effects of age on a new model of tardive dyskinesia. Neurobiol. Aging. 18:1997;623-629.
5. Calvente P.R.V., Araujo C.C.S., Bergamo M., Abilio V.C., D'Almeida V., Ribeiro R.D.A., Frussa-Filho R. The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;401-405.
6. Casey D.E. Tardive dyskinesia - pathophysiology. Bloom F.E., Kupfer D.J. Pyschopharmacology: The Fourth Generation of Progress. 1995;1497-1502 Raven Press, New York.
7. Casey D.E. Tardive dyskinesia: Pathophysiology and animal models. J. Clin. Psychiatry. 61:2000;5-9.
8. Dawson D.A., Masayasu H., Graham D.I., Macrae I.M. The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. Neurosci. Lett. 185:1995;65-69.
9. Dutra R.C., Andreazza A.P., Andreatini S.T., Vital M.A.B.F. Behavioral effects of MK-801 on reserpine-treated mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;487-495.
10. Egan M.E., Apud J., Wyatt R.J. Treatment of tardive dyskinesia. Schizophr. Bull. 23:1997;583-609.
11. Elkashef A.M., Rustin P.E., Bacher N., Barret D. Vitamin E in the treatment of tardive dyskinesia. Am. J. Psychiatry. 147:1990;505-506.
12. Engman L. Expedient synthesis of ebselen and related compounds. J. Org. Chem. 54:1989;2964-2966.
13. Hashimoto T., Ross D.E., Gao X.M., Medoff D.R., Tamminga C.A. Mixture in the distribution of haloperidol-induced oral dyskinesia in the rat supports an animal model of tardive dyskinesia. Psychopharmacology. 137:1998;107-112.
14. Imai H., Masayasu H., Dewar D., Graham D.I., Macrae I.M. Ebselen protects both gray model of focal and white matter in a rodent cerebral ischemia. Stroke. 32:2001;2149-2156.
15. Klawans H.L. The pharmacology of tardive dyskinesias. Am. J. Psychiatry. 130:1973;83-86.
16. Kulkarni S.K., Naidu P.S. Tardive dyskinesia: an update. Drugs Today. 37:2001;97-119.
17. Lohr J.B. Oxygen free radicals and neuropsychiatric illness. Arch. Gen. Psychiatry. 48:1991;1097-1106.
18. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry. 28:1990;535-539.
19. Maiorino M., Roveri A., Coassin M., Ursini F. Kinetic mechanism and substrate specificity of glutathione peroxidase activity of ebselen (PZ 51). Biochem. Pharmacol. 37:1988;2267-2271.
20. Moussaoui S., Obinu M., Daniel N., Reibaud M., Blanchard V., Imperato A. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurol. 166:2000;235-245.
21. Mugesh G., Du Mont W., Sies H. Chemistry of biologically important synthetic organoselenium compounds. Chem. Rev. 101:2001;2125-2179.
22. Müller A., Cadenas E., Graf P., Sies H. A novel biologically active seleno-organic compound: I. Glutathione preoxidase-like activity in vitro and antioxidant capacity of PZ 51(Ebselen). Biochem. Pharmacol. 33:1984;3235-3239.
23. Naidu P.S., Kulkarni S.K. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. Behav. Pharmacol. 12:2001;209-216.
24. Namura S., Nagata I., Takami S., Masayasu H., Kikuchi H. Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice. Stroke. 32:2001;1906-1911.
25. Neisewander J.L., Lucki I., Mcgonigle P. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats. J. Pharmacol. Exp. Ther. 257:1991;850-860.
26. Neisewander J.L., Lucki I., Mcgonigle P. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. Brain Res. 558:1991;27-35.
27. Neiswander J.L., Castañeda E., Davis D.A. Dose-dependent differences in the development of reserpine-induced oral-dyskinesia in rats: support for a model of tardive dyskinesia. Psychopharmacology. 116:1994;79-84.
28. Neisewander J.L., Castaneda E., Davis D.A., Elson H.J., Sussman A.N. Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia. Eur. J. Pharmacol. 305:1996;13-21.
29. Ohkawa H., Ohishi H., Yagi K. Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95:1979;351-358.
30. Porciúncula L.O., Rocha J.B.T., Boeck C.R., Vendite D., Souza D.O. Ebselen prevents excitotoxicity provoked by glutamate in rat cerebellar granule neurons. Neurosci. Lett. 299:2001;217-220.
31. Queiróz C.M.T., Frussa-Filho R. Effects of buspirone on an animal model of tardive dyskinesia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 23:1999;1405-1418.
32. Raghavendra V., Naidu P.S., Kulkarni S.K. Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors. Brain Res. 904:2001;149-152.
33. Rossato J.I., Zeni G., Mello C.F., Rubin M.E., Rocha J.B.T. Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic-acid administration in the rat. Neurosci. Lett. 318:2002;137-140.
34. Rossato J.I., Ketzer L.A., Centurião F.B., Silva S.J.N., Lûdtke D.S., Zeni G., Braga A.L., Rubin M.A., Rocha J.B.T. Antioxidant properties of new chalcogenides against lipid peroxidation in rat brain. Neurochem. Res. 27:2002;297-303.
35. Sachdev P.S. The current status of tardive dyskinesia. Aust. N. Z. J. Psychiatry. 34:2000;355-369.
36. Saito I., Asano T., Sano K., Takakura K., Aba H., Yoshimoto T., Kikuchi H., Ohta T., Ishibashi S. Neuroprotective effect of an antioxidant, Ebselen, in patients with delayed neurological deficits after aneurismal subarachnoid hemorrhage. Neurosurgery. 42:1998;269-278.
37. Shamir E., Barak Y., Shalman I., Laudon M., Zisapel N., Tarrasch R., Elizur A., Weizman R. Melatonin treatment for tardive dyskinesia - a double-blind, placebo-controlled, crossover study. Arch. Gen. Psychiatry. 58:2001;1049-1052.
38. Sussman A.N., Trannguyen L.T.L., Neisewander J.L. Acute reserpine administration elicits long-term spontaneous oral dyskinesia. Eur. J. Pharmacol. 337:1997;157-160.
39. Takasago T., Peters E.E., Graham D.I., Masayasu H., Macrae I.M. Neuroprotective efficacy of ebselen an antioxidant with anti- inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br. J. Pharmacol. 122:1997;1251-1256.
40. Takeuchi H., Ishigooka J., Kobayashi K., Watanabe S., Miura S. Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 22:1998;679-691.
41. Tamaguchi T., Sano K., Takakura K., Saito I., Shinohara Y., Asano T., Yasuhara H. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Stroke. 29:1998;12-17.
42. Tsai G.C., Golf D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry. 155:1998;1207-1213.
43. Turrone P., Remington G., Nobrega J.N. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy? Neurosci. Biobehav. Rev. 26:2002;361-380.
44. Vital M.A.B.F., Frussa-Filho R., Palermo-Neto J. Effects of monosialo-ganglioside GM1 on dopaminergic supersensitivity. Life Sci. 56:1995;2299-2307.
45. Vital M.A.B.F., Frussa-Filho R., Palermo-Neto J. Effects of monosialoganglioside on a new model of tardive dyskinesia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 21:1997;1169-1179.
46. Vital M.A.B.F., Flório J.C., Frussa-Filho, De Lucia R., Tufik S., Palermo-Neto J. Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover. Life Sci. 62:1998;1161-1169.
47. Waddington J.L. Spontaneous orofacial movements induced by very long-term neuroleptic drug administration: phenonomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology. 101:1990;431-447.
48. Wolfarth S., Ossowska K. Can supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia? Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 13:1989;789-840.